kyvero
Market leaders

MMED

MiniMed Group, Inc. (MMED)

Healthcare • Medical Instruments & Supplies

StockNasdaqGSUnited StatesUS60365F1093

17.98 USD +0.56% today Updated 13 Nov 2026 14:35

Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by MiniMed Group, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price history

Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.

All time

Updated 13 Nov 2026 14:35. Information, not advice. Showing the last 12 months. Create a free account to see the whole history

Results

Next results 24 Nov 2026 in 11 days · 08:00 · estimate 0.10
Last results 0.13 vs 0.10 estimated 01 Sep 2026 · Beat +37.8%
Beat the estimate 1 of 3 2 missed · 0 in line
Average surprise -65.9% reported against the estimate, last 3 quarters

Earnings per share: estimate and reported

17 Apr 2026: estimate 0.21 17 Apr 2026: reported 0.08 04/26 03 Jun 2026: estimate -0.22 03 Jun 2026: reported -0.60 06/26 01 Sep 2026: estimate 0.10 01 Sep 2026: reported 0.13 09/26

Estimate Reported: beat Reported: miss In line

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
24 Nov 2026 08:00 0.10 — — Upcoming
01 Sep 2026 06:00 0.10 0.13 +37.8% Beat
03 Jun 2026 06:00 -0.22 -0.60 -171.8% Miss
17 Apr 2026 16:00 0.21 0.08 -63.8% Miss

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2026 3.1B +14.3% -333M -10.7% -1.30 -71.4% -420M
2025 2.7B +10.0% -213M -7.8% -0.76 -90.2% -53M
2024 2.5B +10.0% -112M -4.5% -0.40 -16.7% -107M
2023 2.2B — -96M -4.3% -0.34 — -173M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by week
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
09 Nov 2026 – 13 Nov 2026 In progress 16.98 18.66 16.78 17.98 +7.60% 19,497,829
02 Nov 2026 – 06 Nov 2026 18.38 19.93 16.66 16.71 -8.59% 41,772,100
26 Oct 2026 – 30 Oct 2026 18.29 19.55 18.04 18.28 -0.33% 39,064,400
19 Oct 2026 – 23 Oct 2026 17.52 18.47 17.24 18.34 +4.86% 53,249,400
12 Oct 2026 – 16 Oct 2026 18.87 19.49 16.56 17.49 -11.26% 188,961,400
05 Oct 2026 – 09 Oct 2026 19.69 20.17 18.94 19.71 +0.05% 82,205,200
28 Sep 2026 – 02 Oct 2026 19.97 20.51 19.25 19.70 -1.40% 19,727,000
21 Sep 2026 – 25 Sep 2026 22.14 22.30 19.71 19.98 -8.31% 13,948,800
14 Sep 2026 – 18 Sep 2026 21.50 23.36 21.27 21.79 -3.16% 16,193,700
08 Sep 2026 – 11 Sep 2026 23.16 23.74 22.10 22.50 -3.39% 5,714,500
27 older periods: create a free account to see the whole history

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close
17.88 USD
Market cap
5.0B
Exchange
NasdaqGS
Country
United States
Sector
Healthcare
Industry
Medical Instruments & Supplies
Currency
USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 19.0 / 25
  • Revenue growth of 11.4% a year
Quality Return on equity, net margin and how stable the margins are. 5.6 / 25
  • ROE of -9%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 10.0 / 20
  • Net debt is -0.5× EBITDA
  • Free cash flow yield of -8.4%
Valuation Free cash flow yield and the P/E against its sector. 3.9 / 15
  • Forward P/E 25.4: it is expected to earn money
Analysts How far the analysts' average target is from today's price. 10.0 / 10
  • Analysts' target is +42% from the price
  • Score capped at 60: free cash flow was negative in two of the last three years
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works

Figures

Valuation
FigureValueReading Sector median
P/E (forward) 25.35× Weak 14.16×
Price / book 1.39× Good 3.5×
Price / sales 1.56× Good 3.33×
EV / EBITDA 17.07× Weak 11.19×
Free cash flow yield -8.4% Weak 2.1%
Quality
FigureValueReading Sector median
Gross margin 56.9% Good 54.9%
Operating margin 4% Weak 5.8%
Net margin -9.7% Weak 1.2%
Return on equity -8.7% Weak 4.4%
Growth
FigureValueReading Sector median
Revenue growth / year 11.4% Good 10.1%
Financial health
FigureValueReading Sector median
Debt / equity 0.02× Good 0.4×
Net debt / EBITDA -0.52× Good 1.46×
Current ratio 1.81× Good 2.64×

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Similar shares

Follow MMED and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in